## Jessica K Dyson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/829552/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. Journal of Hepatology, 2014, 60, 110-117.	3.7	487
2	Primary sclerosing cholangitis. Lancet, The, 2018, 391, 2547-2559.	13.7	276
3	Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterology, 2014, 5, 211-218.	1.8	254
4	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2018, 391, 1097-1107.	13.7	140
5	Novel therapeutic targets in primary biliary cirrhosis. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 147-158.	17.8	110
6	Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. Journal of Hepatology, 2016, 64, 234-238.	3.7	85
7	Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2015, 386, 2098-2111.	13.7	76
8	The New Epidemiology of Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 318-328.	3.6	66
9	Unmet clinical need in autoimmune liver diseases. Journal of Hepatology, 2015, 62, 208-218.	3.7	56
10	The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology, 2018, 68, 1487-1497.	7.3	48
11	Treatment of Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2014, 32, 597-604.	1.9	39
12	Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h. Frontline Gastroenterology, 2016, 7, 16-23.	1.8	36
13	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2018, 48, 951-960.	3.7	34
14	New metrics for the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2017, 389, 2053-2080.	13.7	33
15	Review article: unanswered clinical and research questions in autoimmune hepatitisâ€conclusions of the International Autoimmune Hepatitis Group Research Workshop. Alimentary Pharmacology and Therapeutics, 2019, 49, 528-536.	3.7	33
16	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	3.7	33
17	Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis. Hepatology Communications, 2018, 2, 421-436.	4.3	31
18	Fatigue in primary sclerosing cholangitis is associated with sympathetic overâ€activity and increased cardiac output. Liver International, 2015, 35, 1633-1641.	3.9	27

JESSICA K DYSON

#	Article	IF	CITATIONS
19	Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis. JHEP Reports, 2021, 3, 100202.	4.9	22
20	Pregnancy outcomes in women with liver transplants: systematic review and meta-analysis. Hpb, 2020, 22, 1102-1111.	0.3	19
21	Early Molecular Stratification of High-risk Primary Biliary Cholangitis. EBioMedicine, 2016, 14, 65-73.	6.1	17
22	Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clinics in Liver Disease, 2016, 20, 131-142.	2.1	16
23	Adult parenteral nutrition in the North of England: a region-wide audit. BMJ Open, 2017, 7, e012663.	1.9	16
24	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology, 2022, 75, 13-27.	7.3	16
25	Hepatitis B in pregnancy. Frontline Gastroenterology, 2014, 5, 111-117.	1.8	14
26	Managing cognitive symptoms and fatigue in cholestatic liver disease. Expert Review of Gastroenterology and Hepatology, 2021, 15, 235-241.	3.0	13
27	Review article: experimental therapies in autoimmune hepatitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1134-1149.	3.7	12
28	Fatal gastrointestinal histoplasmosis 15 years after orthotopic liver transplantation. World Journal of Gastroenterology, 2017, 23, 7807-7812.	3.3	12
29	Paediatric to adult liver transition services: the state of play in the UK. Clinical Medicine, 2019, 19, 425-426.	1.9	12
30	Prior hysterectomy and discomfort during colonoscopy: a retrospective cohort analysis. Endoscopy, 2014, 46, 493-498.	1.8	11
31	Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma. Hepatology, 2020, 71, 2164-2166.	7.3	11
32	Diagnosis and management of patients with primary biliary cirrhosis. Clinical Liver Disease, 2014, 3, 52-55.	2.1	8
33	Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy. Clinical Medicine, 2014, 14, 551-555.	1.9	6
34	Reply to "Liver failure in human immunodeficiency virus – Hepatitis C virus coinfection treated with sofosbuvir, ledipasvir and antiretroviral therapy― Journal of Hepatology, 2016, 64, 753-754.	3.7	4
35	Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management?. Gastroenterology, 2021, 160, 649-651.	1.3	3
36	Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma. Digestive Diseases and Sciences, 2022, , .	2.3	3

#	Article	IF	CITATIONS
37	UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice. Journal of Hepatology, 2020, 73, 499-501.	3.7	2